Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis
Arthritis & Rheumatology · 2025-08 · 77 (8) · 1052-1062
DOI: 10.1002/art.43146 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 20.04.2025. Verfasst von Michael E Wechsler und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Jewish Health, Denver, Colorado. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Granulomatosis with Polyangiitis, Churg-Strauss Syndrome. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, GSK, Division of Intramural Research, NIAID/NIH.
Abstract (Originalsprache)
Objective
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA. This open‐label extension (OLE) of MIRRA assessed long‐term safety and OCS‐sparing effects of mepolizumab.
Methods
The OLE (NCT03298061) was a multicenter study that enrolled patients from MIRRA who required OCS ≥5 mg/day up to six months after the end of MIRRA. All patients received mepolizumab 300 mg subcutaneously every four weeks plus standard of care until mepolizumab was discontinued or became approved and reimbursed for EGPA in the respective country. Key outcomes included adverse events (AEs) and use of OCS.
Results
One hundred patients were enrolled in the OLE. Mean (SD) and median (min–max) exposure during OLE was 38.5 (27.0) and 27.0 (1.0–89.0) months. On‐treatment AEs were experienced by 98% of patients (43% treatment related; most frequent: injection site reaction [10%]) and serious AEs by 38% of patients (6% treatment related) with no new safety signals versus MIRRA identified. Median (Q1–Q3) OCS dose decreased from 10.0 (7.8–15.0) mg/day at OLE baseline to 5.0 (0.0–10.0) mg/day at study exit. Proportion of patients using OCS >7.5 mg/day decreased from 75% at baseline to 32% at study exit; 28% of patients discontinued OCS.
Conclusion
Long‐term use of mepolizumab to treat EGPA was well tolerated and resulted in sustained reductions in OCS use. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Jewish Health, Denver, Colorado.
- GSK, Durham, North Carolina.
- GSK, Collegeville, Pennsylvania.
- GSK, Stevenage, Hertfordshire, United Kingdom.
- GSK, London, United Kingdom.
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
ORCID-Profile: Paneez Khoury
Förderung
- Intramural NIH HHS
- GSK
- Division of Intramural Research, NIAID/NIH
- GlaxoSmithKline
Zitieren
APA
Wechsler, M. E., Silver, J., Wolff, G., Price, R. G., Verghis, R., Weller, P. F., Merkel, P. A., Khoury, P., & EGPA Mepolizumab Open‐Label Extension Study Group (2025). Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology, 77(8), 1052-1062. https://doi.org/10.1002/art.43146
Vancouver
Wechsler ME, Silver J, Wolff G, Price RG, Verghis R, Weller PF, et al. Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 2025;77(8):1052-1062. doi:10.1002/art.43146
BibTeX
@article{Wechsler2025,
author = {Wechsler, Michael E and Silver, Jared and Wolff, Gerhard and Price, Robert G and Verghis, Rejina and Weller, Peter F and Merkel, Peter A and Khoury, Paneez and EGPA Mepolizumab Open‐Label Extension Study Group, EGPA Mepolizumab Open‐Label Extension Study Group},
title = {Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {8},
pages = {1052--1062},
doi = {10.1002/art.43146}
}
EUVIMED